Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible ...

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible ...

KUALA LUMPUR, June 20, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its…

Cyclacel Raises $3M Through Preferred Stock Deal: New Warrants Unveiled at $0.51-$0.68 Exercise Price

Fresh capital injection extends biotech's runway into Q3 2025. Deal includes 9.8M warrants across three series. See complete financing terms and strategic implications.